Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2021年1月7日 - 11:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the month of January, 2021
Commission
File Number: 001-36000
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant’s name into English)
5
Badner St.
Ramat
Gan,
4365603, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
RAMAT
GAN, Israel — (January 07, 2021)
XTL Biopharmaceuticals
Ltd. (the “Company”) announces today the results of the Annual General Meeting of shareholders of the Company, held
today, Thursday, January 07, 2021, in Bnei Brak, Israel (the “Meeting”). At the Meeting, all of the proposals set
forth in Company’s announcement dated November 25, 2020 were approved by the
required majority of the shareholders. The resolutions were as follows:
1.
|
To
approve the re-appointment of Kesselman & Kesselman, Israeli CPAs, a member firm of PricewaterhouseCoopers International
Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2020 and until our next
annual general meeting of shareholders, and to authorize our Board of Directors to fix such accounting firm’s annual
compensation.
|
|
|
2.
|
To
re-elect Messrs. Alexander Rabinovitch, Dr. Jonathan Schapiro, Shlomo Shalev, Doron Turgeman and Dr. Dobroslav Melamed
to our Board of Directors, each for a term expiring at our next annual general meeting of shareholders (a separate vote
for each director has been taken).
|
3.
|
To
approve the renewal of the Compensation Policy of the Company, in accordance with the requirements of the Israeli Companies
Law 5759-1999 (the “Companies Law”), for a period of three years.
|
About
XTL Biopharmaceuticals Ltd. (XTL)
XTL
Biopharmaceuticals Ltd., is a clinical-stage biotech company. The Company’s lead drug candidate, hCDR1, is a world-class
clinical asset for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren’s
Syndrome (SS). The few treatments currently on the market for these diseases are not effective enough for most patients and some
have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical
studies with data published in more than 40 peer reviewed scientific journals.
XTL
is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included
in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
For
further information, please contact:
Investor
Relations, XTL Biopharmaceuticals Ltd.
Tel:
+972 3 611 6666
Email:
ir@xtlbio.com
www.xtlbio.com
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
|
|
|
Date: January 7, 2021
|
By:
|
/s/
Shlomo Shalev
|
|
|
Shlomo
Shalev
|
|
|
Chief Executive
Officer
|
2
XTL Biopharmaceuticals (NASDAQ:XTLB)
過去 株価チャート
から 10 2024 まで 11 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
過去 株価チャート
から 11 2023 まで 11 2024